Eurand Announces Positive Pharmacokinetic Study Results of Once-a-Day Ondansetron
26. Februar 2008 09:12 ET
|
Eurand N.V.
MILAN, Italy and DAYTON, Ohio, Feb. 26, 2008 (PRIME NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products...
Eurand Granted Priority Review for Zentase NDA
21. Februar 2008 08:00 ET
|
Eurand N.V.
PHILADELPHIA, Feb. 21, 2008 (PRIME NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its...
Eurand Expands Clinical Development and Medical Affairs Management Team
13. Februar 2008 09:00 ET
|
Eurand N.V.
MILAN, Italy and PHILADELPHIA, Feb. 13, 2008 (PRIME NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products...
Eurand to Present At Deutsche Bank 2008 Small and Mid Cap Growth Conference
07. Februar 2008 09:00 ET
|
Eurand N.V.
AMSTERDAM, The Netherlands, Feb. 7, 2008 (PRIME NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on...
Eurand Announces Fourth Quarter 2007 and Year-end Financial Results Conference Call
04. Februar 2008 09:00 ET
|
Eurand N.V.
AMSTERDAM, Feb. 4, 2008 (PRIME NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary...
Eurand Announces Chief Scientific Officer Resigns
09. Januar 2008 10:07 ET
|
Eurand N.V.
AMSTERDAM, Jan. 9, 2008 (PRIME NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary...
Eurand Completes New Drug Application for Zentase
20. Dezember 2007 08:30 ET
|
Eurand N.V.
PHILADELPHIA, Dec. 20, 2007 (PRIME NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its...
Eurand Announces NDA Filing by GSK for Co-development Product
18. Dezember 2007 08:30 ET
|
Eurand N.V.
PHILADELPHIA, Dec. 18, 2007 (PRIME NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its...
Eurand Acquires Specialty Cystic Fibrosis Company
03. Dezember 2007 08:30 ET
|
Eurand N.V.
PHILADELPHIA, Dec. 3, 2007 (PRIME NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX) announced today that Eurand Pharmaceuticals, Inc. has acquired the SourceCF family of companies ("SourceCF") for $6.6 million...
Eurand Completes Bioavailability Study of Zentase
27. November 2007 08:40 ET
|
Eurand N.V.
PHILADELPHIA, Nov. 27, 2007 (PRIME NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX) announced today the completion of a gastrointestinal (GI) bioavailability study on Zentase(tm) (EUR-1008), the Company's lead...